Sign up
IMNM

Immunome Inc (NASDAQ: IMNM)

Healthcare · Biotechnology

$16.78−0.40 (−2.33%)

Last close · Nov 18, 2026 · NASDAQ USD

Set alert

The Quantellect read. IMNM fell 2.33% in the Nov 18 session to $16.78. The borrow fee is 0.28%. 13 active firms cover the stock as of Nov 19, 2026; 12 active firms with targets average $34.25 over 12 months. Descriptive summary of the data on this page, not a recommendation.

Relative valuation—

—

MomentumNeutral

RSI (14) 46.4 (overbought above 70, oversold below 30)

Trend—

—

Short interest14.3% of float

FINRA settlement Oct 30, 2026

IMNM price chart

Price $16.78 · As of Nov 18, 2026, 3:59 PM ET

Open full chart →
Price details unavailable for this range.

Chart loads when this section enters view.

Text price and event history
6M plotted price range (ET)
Range6M
First date—
Last date—
Open—
High—
Low—
Close—
Volume—
Plotted bars0

Plotted OHLCV bars

No price bars are available for this range.

Event records

Event records load after the price chart.

Split-adjusted daily prices · Price as of —

Initial 6M price range summary
Range6M
First close—
Last close—
High—
Low—
Volume—
Open
$17.16Nov 18, 2026 session
Previous close
$17.18Nov 17, 2026 close
Day range
$16.65 – $17.89Nov 18, 2026 session
52-week range—
Volume
1.41MNov 18, 2026 session
Average volume (30 calendar days)—
Market cap—
P/E (TTM)—
Forward P/E—
EPS (TTM)—
Dividend yielddata unavailable —
Beta (5-year monthly vs SPY)—

Price history

IMNM · NASDAQ · USD

Split-adjusted · volume in shares

Price history unavailable

Notable price movement

— · Notable price movement not available

Options flow

— · Options flow not available

Q Score

— · Q Score not available

Quantellect signals

— · Quantellect signals not available

Industry comparison

— · Industry comparison not available

Upcoming events

— · Upcoming events not available

Analyst consensus

Buy

0Strong Buy
12Buy
1Neutral
0Sell
0Strong Sell

Based on 13 active firms as of Nov 19, 2026 (365-day activity window)

12-month price targets (third-party analysts)

Low$24.00
Average$34.25
High$40.00

As of Nov 19, 2026 across 12 active firms with targets. Targets are published by third-party analysts, not by Quantellect.

Full analyst forecast →

Earnings history

EPS, last 8 quarters
EstimateBeatMissMatch
Fiscal periodEst.ActualResult
Q3 2026−$0.60−$0.76—
Q2 2026−$0.51−$0.65—
Q1 2026−$0.59−$0.48—
Annual 2025—−$2.43—
Q3 2025—−$0.65—
Q2 2025—−$0.50—
Q1 2025—−$0.52—
Annual 2024−$0.61−$5.00—

Smart-money activity

— · Smart-money activity not available

All smart-money activity →

News and press releases

All IMNM news →

Company profile

Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It

CEO
Dr. Clay B. Siegall Ph.D.
Headquarters
Bothell, WA, United States
Employees
247
IPO date
Oct 2, 2020
Sector
Healthcare
Industry
Biotechnology

Data sources: exchange quotes delayed 15 minutes, FINRA short interest, SEC filings, OPRA options data and third-party analyst data. Education only. Nothing on this page is a recommendation to buy or sell a security.